Zimmermann-Laband syndrome (ZLS) is a developmental disorder characterized by facial dysmorphism with gingival enlargement, intellectual disability, hypoplasia or aplasia of nails and terminal phalanges, and hypertrichosis 1-4 . We report that heterozygous missense mutations in KCNH1 account for a considerable proportion of ZLS. KCNH1 encodes the voltage-gated K + channel Eag1 (K v 10.1). Patch-clamp recordings showed strong negative shifts in voltage-dependent activation for all but one KCNH1 channel mutant (Gly469Arg). Coexpression of Gly469Arg with wild-type KCNH1 resulted in heterotetrameric channels with reduced conductance at positive potentials but pronounced conductance at negative potentials. These data support a gain-of-function effect for all ZLS-associated KCNH1 mutants. We also identified a recurrent de novo missense change in ATP6V1B2, encoding the B2 subunit of the multimeric vacuolar H + ATPase, in two individuals with ZLS. Structural analysis predicts a perturbing effect of the mutation on complex assembly. Our findings demonstrate that KCNH1 mutations cause ZLS and document genetic heterogeneity for this disorder.
The main clinical characteristics of ZLS (MIM 135500) are gingival enlargement, a bulbous soft nose, thick floppy ears, nail aplasia or hypoplasia, hypertrichosis, joint hyperextensibility, hepato(spleno)megaly, and intellectual disability with or without epilepsy. Most cases are sporadic, suggesting autosomal dominant inheritance with de novo mutations 5 . Two translocations sharing a 3p14.3 breakpoint region, including CACNA2D3 and WNT5A, have been associated with ZLS [6] [7] [8] . CACNA2D3, encoding the auxiliary α2δ-3 subunit of voltage-gated Ca 2+ channels, was found to be disrupted in one individual 7 . However, no additional mutations in CACNA2D3 or WNT5A have been identified 6, 9 nor has any other causative gene for this disease.
We performed whole-exome sequencing on five unrelated subjects with core features of ZLS (subjects 1, 4, 5, 7 and 8; Figs. 1 and 2) and the healthy parents of four of them (Online Methods). Subjects 5, 7 and 8 had been reported previously as having typical ZLS 5, 7, 9 . We processed the whole-exome sequencing data to identify genes shared among probands having functionally relevant variants (new, clinically associated, or of low or unknown frequency), taking into account X-linked, autosomal recessive and autosomal dominant inheritance models (Supplementary Table 1 ). We identified one to seven putatively de novo variants in the four trios (Supplementary Table 2 ). KCNH1 had de novo variants in subjects 1 (c.1399A>G, p.Ile467Val), 4 (c.1405G>A, p.Gly469Arg) and 5 (c.1054C>G, p.Leu352Val) (NM_002238.3; NP_002229.1) (Fig. 1a and Supplementary Table 1) , and subjects 7 and 8 had an identical de novo missense variant in ATP6V1B2 (c.1454G>C, p.Arg485Pro) (NM_001693.3; NP_001684.2) (Fig. 1a and Supplementary Table 1) . We validated these variants by Sanger sequencing, and parental genotyping confirmed their de novo origin. Sequencing confirmed occurrence of the variants in all tissues available for subjects 4 and 5 (mutated KCNH1 l e t t e r s alleles) and subject 7 (ATP6V1B2 mutation) (Supplementary Fig. 1 ). We screened 19 additional individuals exhibiting clinical features fitting ZLS for mutations in each gene. We found that two KCNH1 missense changes-the already-identified c.1399A>G (p.Ile467Val) npg l e t t e r s substitution and c.1042G>A (p.Gly348Arg)-occurred as de novo mutations in subjects 6 and 3, respectively (Fig. 1a) . We documented two heterozygous variants (c.974C>A, p.Ser325Tyr; c.1066G>C, p.Val356Leu) in subject 2 (Fig. 1a) ; both variants were de novo and were demonstrated to be present in cis (Supplementary Fig. 1) . None of the de novo changes were annotated in the dbSNP138, 1000 Genomes Project, Exome Variant Server and ExAC databases. KCNH1 and ATP6V1B2 are predicted to be intolerant to functional genetic variation 10, 11 . All mutations affected residues invariantly observed among vertebrates (Supplementary Fig. 2 ) and were predicted to have a damaging impact on protein function (Supplementary Table 3 ). Overall, the identification of a KCNH1 or ATP6V1B2 mutation in 8 of the 24 patients analyzed indicates further genetic heterogeneity in ZLS.
KCNH1 encodes the Eag1 (K v 10.1) channel, a member of the EAG (ether-à-go-go) family of voltage-gated K + channels 12 . The KCNH1 channel activates at relatively depolarized potentials and conducts a mainly noninactivating, delayed-rectifier K + current 13 . KCNH1 subunits exhibit a typical K v membrane topology, with six transmembrane domains (S1-S6) and a pore-lining loop between S5 and S6 (Fig. 1b) . The affected amino acid residues were located in the voltage-sensing S4 helix (Ser325), the S4-S5 linker (Gly348), and the S5 (Leu352 and Val356) and S6 (Ile467 and Gly469) segments (Fig. 1b) . We explored the structural impact of four of the six mutations by using a homology model for the S5 and S6 helices (Fig. 3) . In the closed state, the Gly469 residues of two KCNH1 monomers are located close to each other, whereas they are farther apart in the open structure. As the p.Gly469Arg change inserts four cationic residues close to each other in the closed state of the homotetramer, this substitution is predicted to impair tetramer formation or favor the open state with a lower conductance due to the presence of cationic residues close to the channel pore (Fig. 3a-c) . A similar effect is expected in heterotetramers of wild-type and mutant subunits. The Ile467, Leu352 and Val356 residues form a tight hydrophobic cluster in the open structure, which rearranges in the closed conformation (Fig. 3a,b,d) . Perturbations of these residues are predicted to affect the closed-open transition. Consistently, mutations in KCNH2 affecting the residues corresponding npg l e t t e r s 14, 15 .
We assessed the functional consequences of the ZLS-associated KCNH1 mutations by patch-clamp experiments on CHO cells expressing wild-type or mutant KCNH1 channels. We recorded outward-rectifying, essentially non-inactivating currents for wild-type KCNH1 and the Gly348Arg, Leu352Val, Ile467Val and Ser325Tyr/ Val356Leu KCNH1 mutants, demonstrating expression of functional channels (Fig. 4a) . The current amplitudes of the mutants did not differ significantly (P = 0.127, one-way ANOVA) from the amplitudes of wild-type KCNH1; all mutant channels, however, exhibited a remarkable shift in the activation threshold to more negative potentials (Fig. 4b) , producing dramatic increases in whole-cell K + conductance in the negative-potential range (Fig. 4c) . This effect resulted from strong leftward shifts in the voltage dependence of channel activation in comparison to wild-type KCNH1 (Fig. 4d and  Supplementary Table 4) . We confirmed these calculated differences in the voltage for half-maximal channel activation by instantaneous tail current measurements (Supplementary Fig. 3) . In comparison to wild-type channels, the mutants exhibited accelerated channel activation and slower deactivation (Supplementary Fig. 4) . Notably, the altered voltage dependence of the double mutant, Ser325Tyr/Val356Leu, resulted from additive effects produced by each individual substitution (Supplementary Fig. 5 and Supplementary Table 4 ). Coexpression of wild-type KCNH1 and the Gly348Arg mutant, which exhibited the smallest shift in voltage dependence, resulted in currents with an intermediate activation threshold and voltage values for half-maximal conductance still 20 mV more negative than those measured for wild-type channels (Fig. 5a-c and  Supplementary Table 4) . These data indicate that the p.Gly348Arg, p.Leu352Val, p.Ile467Val and p.[Ser325Tyr; Val356Leu] substitutions have a gain-of-function effect. In contrast, the Gly469Arg mutant failed to produce voltage-dependent outward currents (Fig. 4a,b) .
We next coexpressed wild-type and Gly469Arg KCNH1 channels in CHO cells. Although the resulting current profile overlapped that observed for the wild-type homotetramer, an additional, smaller component with half-maximal conductance at about −45 mV and a small leakage K + current evident at negative potentials was recorded (Fig. 5d-f and Supplementary Table 4 ). The mean current amplitude at +40 mV corresponded to 69.9% of the respective value for the wildtype channel (s.e.m. of 10.9%; P = 0.12) (Fig. 5e, inset) . As KCNH1 expression levels varied considerably across CHO cells, we used Xenopus laevis oocytes and found that coexpression of Gly469Arg and wild-type KCNH1 resulted in significantly smaller current amplitudes at +40 mV than expression of homomeric wild-type channels (P < 0.001; Supplementary Fig. 6 ). Similar to in CHO cells, we recorded no depolarization-activated currents when homomeric Gly469Arg channels were expressed. These data document a dominant action of the Gly469Arg mutant over the wild-type channel, with reduced K + conductance of the heterotetrameric channels at depolarizing potentials but with pronounced conductance at negative potentials, similar to our findings for the other ZLS-causing KCNH1 mutants. Together, our data show a gain-of-function effect for all disease-associated KCNH1 mutants, similar to the recently identified KCNH5 mutation encoding p.Arg327His in the EAG2 channel in a patient with severe epileptic encephalopathy 16, 17 .
We found ATP6V1B2 to be mutated in two ZLS-affected individuals. ATP6V1B2 encodes the B2 subunit of the vacuolar H + ATPase (V-ATPase), a multisubunit enzyme that mediates acidification in organelles by pumping protons against an electrochemical gradient 18, 19 . V-ATPases comprise a cytoplasmic catalytic V 1 subcomplex and a membrane-embedded V 0 subcomplex (Fig. 1c) . To explore the structural impact of the p.Arg485Pro amino acid change, we generated a homology model of the B2 subunit and inserted it into the crystallographic structure of the A 3 B 3 hexamer of the Enterococcus hirae ATPase 20 . As Arg485 is far from the ATP-binding site, the (16) l467V (9) S325Y/V356L (13) L352V (9) *** npg l e t t e r s p.Arg485Pro substitution is not expected to affect the affinity of the protein for its substrate (Fig. 3e) . Arg485 is however located in an α-helical segment that is predicted to be disrupted by substitution to proline. Moreover, the salt bridge with Asp507 is lost in the mutant (Fig. 3f) . Overall, the arginine-to-proline substitution is predicted to perturb intersubunit interactions within the V 1 subcomplex by destabilizing the C-terminal segment of the B subunit, which is part of the A-B interface and interacts with the E subunit 21 .
In this work, we have provided genetic, structural and functional evidence supporting the dysregulation of KCNH1 in ZLS pathogenesis. KCNH1 is predominantly expressed in the brain 22 ; however, its role in cell cycle control and proliferation is documented in multiple cell lineages, including human bone marrow-derived mesenchymal stem cells [23] [24] [25] [26] [27] . Kcnh1-null mice develop normally and display normal brain morphology and behavior, aside from mild hyperactivity 28 , indicating that, in contrast to hyperactive KCNH1 channels, null alleles of KCNH1 are likely to be tolerated. Consistent with the identification of dominant missense mutations in KCNJ8 and ABCC9, encoding the ATP-sensitive potassium (K ATP ) channel Kir6.1 and its regulatory subunit SUR2, in Cantú syndrome [29] [30] [31] [32] , our findings demonstrate that a balance of K + channel activities is not only critical for neurons but also for other cells and tissues during development.
KCNH1 channels contribute to resting membrane potentials in the vicinity of −40 mV 12 , which are thus close to the activation threshold of L-type voltage-gated Ca 2+ channels 33 . All ZLS-causing KCNH1 mutations induce considerable K + conductance at negative potentials. Stabilization of the membrane potential in a more negative voltage range impedes opening of both voltage-gated Na + and Ca 2+ channels. Thus, functional blockage of these channels could be a secondary effect of the KCNH1 mutations, which may explain the npg l e t t e r s similarity of the gingival enlargement in ZLS-affected subjects to what is observed in some individuals treated with the Na + channel blocker phenytoin 34, 35 or the Ca 2+ channel blocker nifedipine 36 . ZLS belongs to a group of syndromes characterized by considerable clinical overlap and genetic heterogeneity, such as Temple-Baraitser syndrome (TBS; MIM 611816) 37 , dominant deafness-onychodystrophy syndrome (DDOD; MIM 124480) 38 and autosomal recessive deafness, onychodystrophy, osteodystrophy, mental retardation, seizures syndrome (DOORS; MIM 220500) 39 . Intellectual disability, epilepsy, deafness, hypoplasia or aplasia of nails and/or terminal phalanges, and gingival enlargement vary between the different disorders as well as within each condition. The common clinical features in the individuals positive for KCNH1 and ATP6V1B2 mutations reported here include craniofacial dysmorphism, gingival enlargement (preceding any anticonvulsant use), mild to severe intellectual disability, and aplastic or hypoplastic nails and terminal phalanges (Fig. 2, Table 1 and Supplementary Table 5 ). Seizures and/or epilepsy were present in all six subjects with KCNH1 mutations but absent in the two individuals with the ATP6V1B2 mutation, who exhibited coarser facial features. Other clinical features, such as hearing loss and hypertrichosis, were variably present in the eight individuals with a KCNH1 or ATP6V1B2 mutation ( Table 1 and  Supplementary Table 5 ). Recently, de novo KCNH1 gain-of-function mutations have been reported in individuals with TBS 40 , further indicating that both TBS and ZLS belong to a phenotypic continuum that needs to be characterized in the future.
Our genetic data also indicate that alterations of the V-ATPase B2 subunit account for a small proportion of ZLS. ATP6V1B2 is ubiquitously expressed and is the only B subunit isoform expressed in osteoclasts, suggesting an involvement in regulating bone reabsorption [41] [42] [43] . Recently, a heterozygous nonsense ATP6V1B2 mutation, c.1516C>T (p.Arg506*), has been reported in DDOD 44 . Consistent with partial clinical overlap, the ZLS-and DDOD-causing ATP6V1B2 mutations affect the same protein region, which participates in V 1 subcomplex assembly. Truncation of the same segment of ATP6V1B1 disrupts V 1 assembly and impairs ATPase function 21 . Although defective V-ATPase function has been associated with the p.Arg506* alteration 44 and a qualitatively similar effect for the p.Arg485Pro substitution cannot be ruled out, further studies are required to understand the precise functional consequences of these alterations.
In conclusion, we identified KCNH1 and ATP6V1B2 as diseaseassociated genes for ZLS. So far, only hypothetical functional links exist between the two encoded proteins. Both the V-ATPase and KCNH1 have been shown to regulate neurotransmitter release and are important for synaptic transmission 45, 46 . The V-ATPase serves in the acidification of intracellular organelles 47 , and effective proton pumping requires the movement of a counterion. Initial data indicate that K + could act as the counterion 48, 49 . Although no cation channel has yet emerged as a candidate counterion transporter, rapid internalization of plasma membrane-localized KCNH1 and its sorting to lysosomes 50 provide a first clue of the function of KCNH1 in lysosomal conductive pathways. Alternatively, altered acidification of intracellular compartments may lead to disturbances in cellular transport processes in general and to perturbed regulation of KCNH1 trafficking in particular 50, 51 . 
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